Clinical Trial Update: Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD) [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluating atomoxetine versus placebo in children with attention deficit hyperactivity disorder, conducted by Eli Lilly.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• STRATTERA (Atomoxetine hydrochloride)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Attention Deficit Hyperactivity Disorder | Phase 2, Phase 3 | Status: COMPLETED